Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe
- Conditions
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06114238
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400001, Miami, Florida, United States
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT06111586
- Locations
- 🇺🇸
University of Colorado- Site Number : 8400003, Denver, Colorado, United States
🇺🇸University of Texas - Southwestern Medical Center- Site Number : 8400011, Dallas, Texas, United States
🇮🇹Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number : 3800003, Florence, Italy
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 71
- Registration Number
- NCT06106074
- Locations
- 🇺🇸
New Orleans Clinical Research Site Number : 8400001, Knoxville, Tennessee, United States
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 630
- Registration Number
- NCT06102005
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Si- Site Number : 8400058, New York, New York, United States
🇺🇸Clinical Research Of Gastonia- Site Number : 8400013, Gastonia, North Carolina, United States
🇺🇸Bernstein Clinical Research Center- Site Number : 8400016, Cincinnati, Ohio, United States
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06101095
- Locations
- 🇮🇱
Investigational Site Number : 3760003, Tel Aviv, Israel
🇨🇭Investigational Site Number : 7560001, Wetzikon, Switzerland
🇮🇱Investigational Site Number : 3760002, Haifa, Israel
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
- Conditions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT06099704
- Locations
- 🇨🇦
Investigational Site Number : 1240017, Montreal, Quebec, Canada
🇨🇦Investigational Site Number : 1240019, Calgary, Alberta, Canada
🇨🇦Investigational Site Number : 1240021, Calgary, Alberta, Canada
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06087627
- Locations
- 🇩🇪
Investigational site number: 001, Berlin, Germany
🇩🇪Investigational Site Number: 007, Hamburg, Germany
🇩🇪Investigational Site Number: 005, Düren, Germany
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 180
- Registration Number
- NCT06082037
- Locations
- 🇺🇸
Vanderbilt University Medical Center- Site Number : 8400018, Nashville, Tennessee, United States
🇨🇦Investigational Site Number : 1240002, Edmonton, Alberta, Canada
🇨🇳Investigational Site Number : 1560005, Hefei, China
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 207
- Registration Number
- NCT06073119
- Locations
- 🇺🇸
Scottsdale Clinical Trials Site Number : 8400025, Scottsdale, Arizona, United States
🇺🇸First OC Dermatology Site Number : 8400005, Fountain Valley, California, United States
🇺🇸Dermatology Research Associates Site Number : 8400019, Los Angeles, California, United States
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT06073093
- Locations
- 🇺🇸
Amicis Research Center- Site Number : 8400023, Northridge, California, United States
🇺🇸Inland Rheumatology & Osteoporosis Medical Group- Site Number : 8400004, Upland, California, United States
🇺🇸UF Health Deerwood Park- Site Number : 8400020, Jacksonville, Florida, United States